Real-World Experience of Hemoxin R Plus (Nikosan K Plus): Retrospective Analysis on 150 Patients

Sickle cell disease (SCD) is amongst the most common genetic hematological disorders. Hand-foot syndrome (swelling), pain and anemia are some of the very common complications of the disease. In Sickle cell anemia, the number of healthy RBCs decrease which results in reduction of oxygen in the tissue...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of ayurveda and pharma research 2022-06, p.50-54
Hauptverfasser: Megha Mangla, Anish Mody, Purviben Choudhari, Nitin R Bhasin, Chaggan Choudhary
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 54
container_issue
container_start_page 50
container_title International journal of ayurveda and pharma research
container_volume
creator Megha Mangla
Anish Mody
Purviben Choudhari
Nitin R Bhasin
Chaggan Choudhary
description Sickle cell disease (SCD) is amongst the most common genetic hematological disorders. Hand-foot syndrome (swelling), pain and anemia are some of the very common complications of the disease. In Sickle cell anemia, the number of healthy RBCs decrease which results in reduction of oxygen in the tissues. Majority of the SCD patients are from low socio-economic strata and can barely afford costly treatment modalities. Retrospective analysis was done on 150 patients who consumed a proprietary Ayurvedic medicine, Hemoxin R Plus (Nikosan K Plus). Objectives: Sickle cell anemia impacts quality of life of patients which include pains including joint pain, abdominal pain, and total body pain. It also leads to breathlessness, weakness or fatigue and hence difficulties in doing daily chores.  Our aim was to evaluate safety and efficacy of Hemoxin R Plus, an Ayurvedic medicine in improving quality of life in patients having SCA. Materials and Methods: This was a retrospective analysis. Hospital records of the patients were used and reviewed for the analysis. The doctors who treated the patients collected the data from the medical records department. Wilcoxon signed rank test was applied for analysis. Parameters related to the quality of life were studied. The parameters considered were pain (whole body, abdominal, limbs/joints, back), fatigue, breathlessness, difficulty in doing daily activities and absenteeism (school/job). Results: For every parameter considered for analysis, the probability value (p value) was found to be
doi_str_mv 10.47070/ijapr.v10i5.2379
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_47070_ijapr_v10i5_2379</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_47070_ijapr_v10i5_2379</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_47070_ijapr_v10i5_23793</originalsourceid><addsrcrecordid>eNqdj8FqAjEURUOpUGn9gO7esi5mfMkoYborYhEEkUHoMobpG4iNyZA3iv69dpB-QFf33sW5cIR4lZhPNWqcuL1tU36S6Ga5KnT5IIaqUCrDUuLjX0f1JEbMe0SUWqlyqodiV5H12VdM_hsW55aSo1ATxAaWdIhnF6CCjT8yvK3dT2QbYNXv8TtU1KXILdWdOxF8BOsv7BhiADlD2NjudtXxixg01jON7vks5OdiO19m9Q3mRI1pkzvYdDESTW9jehvT25hfm-I_zBWkiVTR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Real-World Experience of Hemoxin R Plus (Nikosan K Plus): Retrospective Analysis on 150 Patients</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Megha Mangla ; Anish Mody ; Purviben Choudhari ; Nitin R Bhasin ; Chaggan Choudhary</creator><creatorcontrib>Megha Mangla ; Anish Mody ; Purviben Choudhari ; Nitin R Bhasin ; Chaggan Choudhary</creatorcontrib><description>Sickle cell disease (SCD) is amongst the most common genetic hematological disorders. Hand-foot syndrome (swelling), pain and anemia are some of the very common complications of the disease. In Sickle cell anemia, the number of healthy RBCs decrease which results in reduction of oxygen in the tissues. Majority of the SCD patients are from low socio-economic strata and can barely afford costly treatment modalities. Retrospective analysis was done on 150 patients who consumed a proprietary Ayurvedic medicine, Hemoxin R Plus (Nikosan K Plus). Objectives: Sickle cell anemia impacts quality of life of patients which include pains including joint pain, abdominal pain, and total body pain. It also leads to breathlessness, weakness or fatigue and hence difficulties in doing daily chores.  Our aim was to evaluate safety and efficacy of Hemoxin R Plus, an Ayurvedic medicine in improving quality of life in patients having SCA. Materials and Methods: This was a retrospective analysis. Hospital records of the patients were used and reviewed for the analysis. The doctors who treated the patients collected the data from the medical records department. Wilcoxon signed rank test was applied for analysis. Parameters related to the quality of life were studied. The parameters considered were pain (whole body, abdominal, limbs/joints, back), fatigue, breathlessness, difficulty in doing daily activities and absenteeism (school/job). Results: For every parameter considered for analysis, the probability value (p value) was found to be &lt;0.05, confirming the statistical significance in reduction of symptoms. Hemoxin R Plus was found to be safe in the dose administered, as there were no adverse events reported. Conclusion: Capsule Hemoxin R Plus can be used for of the management of sickle cell anemia in pain reduction and in improving the quality of life.</description><identifier>ISSN: 2322-0902</identifier><identifier>EISSN: 2322-0910</identifier><identifier>DOI: 10.47070/ijapr.v10i5.2379</identifier><language>eng</language><ispartof>International journal of ayurveda and pharma research, 2022-06, p.50-54</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Megha Mangla</creatorcontrib><creatorcontrib>Anish Mody</creatorcontrib><creatorcontrib>Purviben Choudhari</creatorcontrib><creatorcontrib>Nitin R Bhasin</creatorcontrib><creatorcontrib>Chaggan Choudhary</creatorcontrib><title>Real-World Experience of Hemoxin R Plus (Nikosan K Plus): Retrospective Analysis on 150 Patients</title><title>International journal of ayurveda and pharma research</title><description>Sickle cell disease (SCD) is amongst the most common genetic hematological disorders. Hand-foot syndrome (swelling), pain and anemia are some of the very common complications of the disease. In Sickle cell anemia, the number of healthy RBCs decrease which results in reduction of oxygen in the tissues. Majority of the SCD patients are from low socio-economic strata and can barely afford costly treatment modalities. Retrospective analysis was done on 150 patients who consumed a proprietary Ayurvedic medicine, Hemoxin R Plus (Nikosan K Plus). Objectives: Sickle cell anemia impacts quality of life of patients which include pains including joint pain, abdominal pain, and total body pain. It also leads to breathlessness, weakness or fatigue and hence difficulties in doing daily chores.  Our aim was to evaluate safety and efficacy of Hemoxin R Plus, an Ayurvedic medicine in improving quality of life in patients having SCA. Materials and Methods: This was a retrospective analysis. Hospital records of the patients were used and reviewed for the analysis. The doctors who treated the patients collected the data from the medical records department. Wilcoxon signed rank test was applied for analysis. Parameters related to the quality of life were studied. The parameters considered were pain (whole body, abdominal, limbs/joints, back), fatigue, breathlessness, difficulty in doing daily activities and absenteeism (school/job). Results: For every parameter considered for analysis, the probability value (p value) was found to be &lt;0.05, confirming the statistical significance in reduction of symptoms. Hemoxin R Plus was found to be safe in the dose administered, as there were no adverse events reported. Conclusion: Capsule Hemoxin R Plus can be used for of the management of sickle cell anemia in pain reduction and in improving the quality of life.</description><issn>2322-0902</issn><issn>2322-0910</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqdj8FqAjEURUOpUGn9gO7esi5mfMkoYborYhEEkUHoMobpG4iNyZA3iv69dpB-QFf33sW5cIR4lZhPNWqcuL1tU36S6Ga5KnT5IIaqUCrDUuLjX0f1JEbMe0SUWqlyqodiV5H12VdM_hsW55aSo1ATxAaWdIhnF6CCjT8yvK3dT2QbYNXv8TtU1KXILdWdOxF8BOsv7BhiADlD2NjudtXxixg01jON7vks5OdiO19m9Q3mRI1pkzvYdDESTW9jehvT25hfm-I_zBWkiVTR</recordid><startdate>20220605</startdate><enddate>20220605</enddate><creator>Megha Mangla</creator><creator>Anish Mody</creator><creator>Purviben Choudhari</creator><creator>Nitin R Bhasin</creator><creator>Chaggan Choudhary</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20220605</creationdate><title>Real-World Experience of Hemoxin R Plus (Nikosan K Plus): Retrospective Analysis on 150 Patients</title><author>Megha Mangla ; Anish Mody ; Purviben Choudhari ; Nitin R Bhasin ; Chaggan Choudhary</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_47070_ijapr_v10i5_23793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Megha Mangla</creatorcontrib><creatorcontrib>Anish Mody</creatorcontrib><creatorcontrib>Purviben Choudhari</creatorcontrib><creatorcontrib>Nitin R Bhasin</creatorcontrib><creatorcontrib>Chaggan Choudhary</creatorcontrib><collection>CrossRef</collection><jtitle>International journal of ayurveda and pharma research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Megha Mangla</au><au>Anish Mody</au><au>Purviben Choudhari</au><au>Nitin R Bhasin</au><au>Chaggan Choudhary</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real-World Experience of Hemoxin R Plus (Nikosan K Plus): Retrospective Analysis on 150 Patients</atitle><jtitle>International journal of ayurveda and pharma research</jtitle><date>2022-06-05</date><risdate>2022</risdate><spage>50</spage><epage>54</epage><pages>50-54</pages><issn>2322-0902</issn><eissn>2322-0910</eissn><abstract>Sickle cell disease (SCD) is amongst the most common genetic hematological disorders. Hand-foot syndrome (swelling), pain and anemia are some of the very common complications of the disease. In Sickle cell anemia, the number of healthy RBCs decrease which results in reduction of oxygen in the tissues. Majority of the SCD patients are from low socio-economic strata and can barely afford costly treatment modalities. Retrospective analysis was done on 150 patients who consumed a proprietary Ayurvedic medicine, Hemoxin R Plus (Nikosan K Plus). Objectives: Sickle cell anemia impacts quality of life of patients which include pains including joint pain, abdominal pain, and total body pain. It also leads to breathlessness, weakness or fatigue and hence difficulties in doing daily chores.  Our aim was to evaluate safety and efficacy of Hemoxin R Plus, an Ayurvedic medicine in improving quality of life in patients having SCA. Materials and Methods: This was a retrospective analysis. Hospital records of the patients were used and reviewed for the analysis. The doctors who treated the patients collected the data from the medical records department. Wilcoxon signed rank test was applied for analysis. Parameters related to the quality of life were studied. The parameters considered were pain (whole body, abdominal, limbs/joints, back), fatigue, breathlessness, difficulty in doing daily activities and absenteeism (school/job). Results: For every parameter considered for analysis, the probability value (p value) was found to be &lt;0.05, confirming the statistical significance in reduction of symptoms. Hemoxin R Plus was found to be safe in the dose administered, as there were no adverse events reported. Conclusion: Capsule Hemoxin R Plus can be used for of the management of sickle cell anemia in pain reduction and in improving the quality of life.</abstract><doi>10.47070/ijapr.v10i5.2379</doi></addata></record>
fulltext fulltext
identifier ISSN: 2322-0902
ispartof International journal of ayurveda and pharma research, 2022-06, p.50-54
issn 2322-0902
2322-0910
language eng
recordid cdi_crossref_primary_10_47070_ijapr_v10i5_2379
source EZB-FREE-00999 freely available EZB journals
title Real-World Experience of Hemoxin R Plus (Nikosan K Plus): Retrospective Analysis on 150 Patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A11%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real-World%20Experience%20of%20Hemoxin%20R%20Plus%20(Nikosan%20K%20Plus):%20Retrospective%20Analysis%20on%20150%20Patients&rft.jtitle=International%20journal%20of%20ayurveda%20and%20pharma%20research&rft.au=Megha%20Mangla&rft.date=2022-06-05&rft.spage=50&rft.epage=54&rft.pages=50-54&rft.issn=2322-0902&rft.eissn=2322-0910&rft_id=info:doi/10.47070/ijapr.v10i5.2379&rft_dat=%3Ccrossref%3E10_47070_ijapr_v10i5_2379%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true